{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:17:04Z","timestamp":1790788624561,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"\u201cParrainage Cancers Gyn\u00e9cologiques\u201d program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Knowing the homologous recombination deficiency (HRD) status in advanced epithelial ovarian cancer (EOC) is vital for patient management. HRD is determined by BRCA1\/BRCA2 pathogenic variants or genomic instability. However, tumor DNA analysis is inconclusive in 15\u201319% of cases. Peritoneal fluid, available in\u2009&gt;\u200995% of advanced EOC cases, could serve as an alternative source of cell-free tumor DNA (cftDNA) for HRD testing. Limited data show the feasibility of cancer panel gene testing on ascites cfDNA but no study, to date, has investigated HRD testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected ascites\/peritoneal washings from 53 EOC patients (19 from retrospective cohort and 34 from prospective cohort) and performed a Cancer Gene Panel (CGP) using NGS for TP53\/HR genes and shallow Whole Genome Sequencing (sWGS) for genomic instability on cfDNA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>cfDNA was detectable in 49 out of 53 patients (92.5%), including those with limited peritoneal fluid. Median cfDNA was 3700\u00a0ng\/ml, with a turnaround time of 21\u00a0days. TP53 pathogenic variants were detected in 86% (42\/49) of patients, all with HGSOC. BRCA1 and BRCA2 pathogenic variants were found in 14% (7\/49) and 10% (5\/49) of cases, respectively. Peritoneal cftDNA showed high sensitivity (97%), specificity (83%), and concordance (95%) with tumor-based TP53 variant detection. NGS CGP on cftDNA identified BRCA2 pathogenic variants in one case where tumor-based testing failed. sWGS on cftDNA provided informative results even when tumor-based genomic instability testing failed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Profiling cftDNA from peritoneal fluid is feasible, providing a significant amount of tumor DNA. This fast and reliable approach enables HRD testing, including BRCA1\/2 mutations and genomic instability assessment. HRD testing on cfDNA from peritoneal fluid should be offered to all primary laparoscopy patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-023-01864-1","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T02:02:17Z","timestamp":1699236137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid"],"prefix":"10.1186","volume":"22","author":[{"given":"Cyril","family":"Roussel-Simonin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Blanc-Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseline","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Vasseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Le Formal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Chardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Yaniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Gouy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Maulard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Scherier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Sanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Cotteret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Mauny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Zaccarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"1864_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284\u201396.","journal-title":"CA Cancer J Clin."},{"key":"1864_CR2","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","volume":"5","author":"PA Konstantinopoulos","year":"2015","unstructured":"Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D\u2019Andrea AD. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov. 2015;5:1137\u201354.","journal-title":"Cancer Discov"},{"key":"1864_CR3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","unstructured":"The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"},{"key":"1864_CR4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379:2495\u2013505.","journal-title":"N Engl J Med"},{"key":"1864_CR5","doi-asserted-by":"publisher","unstructured":"Monk, B. J. et al. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45). J Clin Oncol JCO2201003 (2022) https:\/\/doi.org\/10.1200\/JCO.22.01003.","DOI":"10.1200\/JCO.22.01003"},{"key":"1864_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381:2391\u2013402.","journal-title":"N Engl J Med"},{"key":"1864_CR7","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381:2416\u201328.","journal-title":"N Engl J Med"},{"key":"1864_CR8","doi-asserted-by":"publisher","unstructured":"Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer | NEJM. https:\/\/doi.org\/10.1056\/NEJMoa1909707.","DOI":"10.1056\/NEJMoa1909707"},{"key":"1864_CR9","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393:1240\u201353.","journal-title":"Lancet"},{"key":"1864_CR10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41571-022-00660-y","volume":"19","author":"A Tivey","year":"2022","unstructured":"Tivey A, Church M, Rothwell D, Dive C, Cook N. Circulating tumour DNA \u2014 looking beyond the blood. Nat Rev Clin Oncol. 2022;19:600\u201312.","journal-title":"Nat Rev Clin Oncol"},{"key":"1864_CR11","unstructured":"Bayle, A. et al. Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study. Ann Oncol 0, (2023)."},{"key":"1864_CR12","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual J, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022;33:750\u201368.","journal-title":"Ann Oncol"},{"key":"1864_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/15384047.2018.1504720","volume":"20","author":"S Zhou","year":"2019","unstructured":"Zhou S, et al. Next-generation sequencing reveals mutational accordance between cell-free DNA from plasma, malignant pleural effusion and ascites and directs targeted therapy in a gastric cancer patient. Cancer Biol Ther. 2019;20:15\u201320.","journal-title":"Cancer Biol Ther"},{"key":"1864_CR14","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1158\/1535-7163.MCT-16-0436","volume":"16","author":"H Husain","year":"2017","unstructured":"Husain H, et al. Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology. Mol Cancer Ther. 2017;16:948\u201355.","journal-title":"Mol Cancer Ther"},{"key":"1864_CR15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4143\/crt.2019.700","volume":"52","author":"M-R Han","year":"2020","unstructured":"Han M-R, et al. Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer. Cancer Res Treat. 2020;52:779\u201388.","journal-title":"Cancer Res Treat"},{"key":"1864_CR16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ygyno.2021.06.028","volume":"162","author":"B Werner","year":"2021","unstructured":"Werner B, et al. Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer. Gynecol Oncol. 2021;162:720\u20137.","journal-title":"Gynecol Oncol"},{"key":"1864_CR17","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1093\/bioinformatics\/btaa261","volume":"36","author":"A Eeckhoutte","year":"2020","unstructured":"Eeckhoutte A, et al. ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing. Bioinformatics. 2020;36:3888\u20139.","journal-title":"Bioinformatics"},{"key":"1864_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10555-016-9629-x","volume":"35","author":"AR Thierry","year":"2016","unstructured":"Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35:347\u201376.","journal-title":"Cancer Metastasis Rev"},{"issue":"1suppl_1","key":"1864_CR19","doi-asserted-by":"publisher","first-page":"100811","DOI":"10.1016\/esmoop\/esmoop100811","volume":"8","author":"C Callens","year":"2023","unstructured":"Callens C, et al. 38MO - Validation study of the shallowHRDv2 assay for Homologous Recombination Deficiency (HRD) detection in high-grade ovarian carcinomas (HGOC) in the first-line setting, from the phase III PAOLA-1\/ENGOT-ov25 trial. Ann Oncol. 2023;8(1suppl_1):100811\u2013100811. https:\/\/doi.org\/10.1016\/esmoop\/esmoop100811.","journal-title":"Ann Oncol"},{"issue":"1suppl_1","key":"1864_CR20","doi-asserted-by":"publisher","first-page":"100811","DOI":"10.1016\/esmoop\/esmoop100811","volume":"8","author":"R Boidot","year":"2023","unstructured":"Boidot R, et al. 39MO - Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer. Ann Oncol. 2023;8(1suppl_1):100811\u2013100811. https:\/\/doi.org\/10.1016\/esmoop\/esmoop100811.","journal-title":"Ann Oncol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01864-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-023-01864-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01864-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T02:03:49Z","timestamp":1699236229000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-023-01864-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1864"],"URL":"https:\/\/doi.org\/10.1186\/s12943-023-01864-1","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]},"assertion":[{"value":"20 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent authorizing the use of biological samples obtained during their routine diagnosis and treatment as part of the prospective academic research study OvBIOMARK (NCT03010124). This study received ethical approval from the Ethic Committee\/IRB\/CPP, ensuring participant rights. Confidentiality and privacy were rigorously maintained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}